Evolution of Therapy for Relapsed/Refractory Multiple Myeloma

被引：4
作者：
Castillo, Jorge J. [1 ]
机构：
[1] Dana Farber Canc Inst, 450 Brookline Ave,M221, Boston, MA 02215 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 11期
关键词：
PLUS POMALIDOMIDE; DEXAMETHASONE; LENALIDOMIDE; DARATUMUMAB; BORTEZOMIB;
D O I：
10.6004/jnccn.2019.5035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With so many recent advances in relapsed/refractory multiple myeloma, keeping abreast with current treatment recommendations can be challenging. Novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have all been added to the armamentarium, and the choice of which of these drugs or drug combinations to use depends on individual disease-related and patient-related factors, previous therapies, and treatment toxicities. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jorge J. Castillo provided an overview of the myriad treatments available for patients with relapsed/refractory multiple myeloma, as well as therapies on the horizon.
引用
收藏
页码：1433 / 1436
页数：4
相关论文
共 50 条
[21]   Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study [J].
Sunami, Kazutaka ;
Murakami, Hiroyuki ;
Tagashira, Hisashi ;
Ueda, Hiroko ;
Moriyama, Takashi ;
Ishikawa, Tatsunori ;
Yoshioka, Takanori ;
Makita, Masanori .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (12) :2151-2157
[22]   Promising therapeutic approaches for relapsed/refractory multiple myeloma [J].
Ni, Beiwen ;
Hou, Jian .
HEMATOLOGY, 2022, 27 (01) :343-352
[23]   Management of Relapsed and Refractory Multiple Myeloma: Recent advances [J].
Rathnam, Krishnakumar ;
Saju, S. V. V. ;
Honey, Susan Raju .
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2022, 43 (06) :458-472
[24]   Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma [J].
Cai, Hongfu ;
Zhang, Longfeng ;
Li, Na ;
Zheng, Bin ;
Liu, Maobai .
LEUKEMIA & LYMPHOMA, 2019, 60 (12) :2951-2959
[25]   Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany [J].
Basic, Edin ;
Kappel, Mathias ;
Misra, Arpit ;
Sellner, Leopold ;
Ratsch, Boris A. ;
Ostwald, Dennis A. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (09) :1351-1361
[26]   Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee [J].
Kumar, Shaji ;
Baizer, Lawrence ;
Callander, Natalie S. ;
Giralt, Sergio A. ;
Hillengass, Jens ;
Freidlin, Boris ;
Hoering, Antje ;
Richardson, Paul G. ;
Schwartz, Elena I. ;
Reiman, Anthony ;
Lentzsch, Suzanne ;
McCarthy, Philip L. ;
Jagannath, Sundar ;
Yee, Andrew J. ;
Little, Richard F. ;
Raje, Noopur S. .
BLOOD CANCER JOURNAL, 2022, 12 (06)
[27]   Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma [J].
Bapatla, Anusha ;
Kaul, Arunima ;
Dhalla, Paramvijay Singh ;
Armenta-Quiroga, Ana S. ;
Khalid, Raheela ;
Garcia, Jian ;
Khan, Safeera .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
[28]   Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma [J].
Moustafa, Muhamad Alhaj ;
Parrondo, Ricardo ;
Abdulazeez, Mays F. ;
Roy, Vivek ;
Sher, Taimur ;
Alegria, Victoria R. ;
Warsame, Rahma M. ;
Fonseca, Rafael ;
Rasheed, Ahsan ;
Gonsalves, Wilson I. ;
Kourelis, Taxiarchis ;
Kapoor, Prashant ;
Buadi, Francis K. ;
Dingli, David ;
Hayman, Suzanne R. ;
Reeder, Craig B. ;
Chanan-Khan, Asher A. ;
Ailawadhi, Sikander .
ANTI-CANCER DRUGS, 2024, 35 (01) :63-69
[29]   BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA [J].
Michael, M. ;
Bruns, I. ;
Boelke, E. ;
Zohren, F. ;
Czibere, A. ;
Safaian, N. N. ;
Ncumann, F. ;
Haas, R. ;
Kobbe, G. ;
Fenk, R. .
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (01) :13-19
[30]   Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma [J].
Lamb, Yvette N. .
DRUGS, 2018, 78 (14) :1481-1488
12345